HIGHLIGHTS
SUMMARY
In a typical RSV season, among adults ≥ 65 years of age or older or adults with underlying cardiopulmonary diseases hospitalized with laboratoryconfirmed RSV infection, RSV infection accounts for an estimated 11% of hospitalizations for pneumonia, 11% of hospitalizations for chronic obstructive pulmonary disease, 5% of hospitalizations for congestive heart failure, and 7% of hospitalizations for asthma. There are a number of RSV vaccine and therapeutic candidates being investigated in clinical trials, but there are no existing clinical outcome assessment measures for RSV symptom severity for use in clinical trials that meet the standards described . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.